Valeant Pharmaceuticals International Inc., of Laval, Quebec, said that VRX Escrow Corp., a newly formed wholly owned Canadian subsidiary of the company, has priced $2 billion aggregate principal amount of 5.375 percent senior unsecured notes due 2020, $3.25 billion aggregate principal amount of 5.875 percent senior unsecured notes due 2023, €1.5 billion (US$1.6 billion) aggregate principal amount of 4.50 percent senior unsecured notes due 2023, and $3.25 billion aggregate principal amount of 6.125 percent senior unsecured notes due 2025.